-
Je něco špatně v tomto záznamu ?
Long-term outcomes and reverse remodelling in recently diagnosed unexplained left ventricular systolic dysfunction
P. Kuchynka, J. Podzimkova, J. Marek, BA. Danek, I. Vitkova, M. Kreidlova, L. Roblova, T. Kovarnik, S. Simek, J. Horak, J. Habasko, A. Linhart, T. Palecek
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
Charles University Research Program Cooperatio Cardiovascular Science
NLK
Directory of Open Access Journals
od 2014
Free Medical Journals
od 2014
PubMed Central
od 2015
Europe PubMed Central
od 2015
ProQuest Central
od 2014-09-01
Open Access Digital Library
od 2014-01-01
Open Access Digital Library
od 2014-09-01
Health & Medicine (ProQuest)
od 2014-09-01
Wiley-Blackwell Open Access Titles
od 2014
ROAD: Directory of Open Access Scholarly Resources
od 2014
PubMed
38204216
DOI
10.1002/ehf2.14643
Knihovny.cz E-zdroje
- MeSH
- dilatační kardiomyopatie * MeSH
- dysfunkce levé srdeční komory * komplikace MeSH
- funkce levé komory srdeční fyziologie MeSH
- lidé MeSH
- prognóza MeSH
- srdeční selhání * MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: In patients with recently diagnosed non-ischaemic LV systolic dysfunction, left ventricular reverse remodelling (LVRR) and favourable prognosis has been documented in studies with short-term follow-up. The aim of our study was to assess the long-term clinical course and stability of LVRR in these patients. METHODS AND RESULTS: We prospectively studied 133 patients (37 women; 55 [interquartile range 46, 61] years) with recently diagnosed unexplained LV systolic dysfunction, with heart failure symptoms lasting <6 months and LV ejection fraction <40% persisting after at least 1 week of therapy. All patients underwent endomyocardial biopsy (EMB) at the time of diagnosis and serial echocardiographic and clinical follow-up over 5 years. LVRR was defined as the combined presence of (1) LVEF ≥ 50% or increase in LVEF ≥ 10% points and (2) decrease in LV end-diastolic diameter index (LVEDDi) ≥ 10% or (3) LVEDDi ≤ 33 mm/m2. LVRR was observed in 46% patients at 1 year, in 60% at 2 years and 50% at 5 years. Additionally, 2% of patients underwent heart transplantation and 12% experienced heart failure hospitalization. During 5-year follow-up, 23 (17%) of the study cohort died. In multivariate analysis, independent predictors of mortality were baseline right atrial size (OR 1.097, CI 1.007-1.196), logBNP level (OR 2.02, CI 1.14-3.56), and PR interval (OR 1.02, CI 1.006-1.035) (P < 0.05 for all). The number of macrophages on EMB was associated with overall survival in univariate analysis only. LVRR at 1 year of follow-up was associated with a lower rate of mortality and heart failure hospitalization (P = 0.025). In multivariate analysis, independent predictors of LVRR were left ventricular end-diastolic volume index (OR 0.97, CI 0.946-0.988), LVEF (OR 0.89, CI 0.83-0.96), and diastolic blood pressure (OR 1.04, CI 1.01-1.08) (P < 0.05 for all). CONCLUSIONS: LVRR occurs in over half of patients with recent onset unexplained LV systolic dysfunction during first 2 years of optimally guided heart failure therapy and then remains relatively stable during 5-year follow-up. Normalization of adverse LV remodelling corresponds to a low rate of mortality and heart failure hospitalizations during long-term follow-up.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006589
- 003
- CZ-PrNML
- 005
- 20240423155356.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ehf2.14643 $2 doi
- 035 __
- $a (PubMed)38204216
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kuchynka, Petr $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 245 10
- $a Long-term outcomes and reverse remodelling in recently diagnosed unexplained left ventricular systolic dysfunction / $c P. Kuchynka, J. Podzimkova, J. Marek, BA. Danek, I. Vitkova, M. Kreidlova, L. Roblova, T. Kovarnik, S. Simek, J. Horak, J. Habasko, A. Linhart, T. Palecek
- 520 9_
- $a AIMS: In patients with recently diagnosed non-ischaemic LV systolic dysfunction, left ventricular reverse remodelling (LVRR) and favourable prognosis has been documented in studies with short-term follow-up. The aim of our study was to assess the long-term clinical course and stability of LVRR in these patients. METHODS AND RESULTS: We prospectively studied 133 patients (37 women; 55 [interquartile range 46, 61] years) with recently diagnosed unexplained LV systolic dysfunction, with heart failure symptoms lasting <6 months and LV ejection fraction <40% persisting after at least 1 week of therapy. All patients underwent endomyocardial biopsy (EMB) at the time of diagnosis and serial echocardiographic and clinical follow-up over 5 years. LVRR was defined as the combined presence of (1) LVEF ≥ 50% or increase in LVEF ≥ 10% points and (2) decrease in LV end-diastolic diameter index (LVEDDi) ≥ 10% or (3) LVEDDi ≤ 33 mm/m2. LVRR was observed in 46% patients at 1 year, in 60% at 2 years and 50% at 5 years. Additionally, 2% of patients underwent heart transplantation and 12% experienced heart failure hospitalization. During 5-year follow-up, 23 (17%) of the study cohort died. In multivariate analysis, independent predictors of mortality were baseline right atrial size (OR 1.097, CI 1.007-1.196), logBNP level (OR 2.02, CI 1.14-3.56), and PR interval (OR 1.02, CI 1.006-1.035) (P < 0.05 for all). The number of macrophages on EMB was associated with overall survival in univariate analysis only. LVRR at 1 year of follow-up was associated with a lower rate of mortality and heart failure hospitalization (P = 0.025). In multivariate analysis, independent predictors of LVRR were left ventricular end-diastolic volume index (OR 0.97, CI 0.946-0.988), LVEF (OR 0.89, CI 0.83-0.96), and diastolic blood pressure (OR 1.04, CI 1.01-1.08) (P < 0.05 for all). CONCLUSIONS: LVRR occurs in over half of patients with recent onset unexplained LV systolic dysfunction during first 2 years of optimally guided heart failure therapy and then remains relatively stable during 5-year follow-up. Normalization of adverse LV remodelling corresponds to a low rate of mortality and heart failure hospitalizations during long-term follow-up.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a funkce levé komory srdeční $x fyziologie $7 D016277
- 650 12
- $a dilatační kardiomyopatie $7 D002311
- 650 12
- $a dysfunkce levé srdeční komory $x komplikace $7 D018487
- 650 12
- $a srdeční selhání $7 D006333
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Podzimkova, Jana $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Marek, Josef $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Danek, Barbara Anna $u Division of Cardiology, University of Washington Medical Center, Seattle, WA, USA
- 700 1_
- $a Vitkova, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Kreidlova, Miluse $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Roblova, Lenka $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Kovarnik, Tomas $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Simek, Stanislav $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Horak, Jan $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Habasko, Jan $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Linhart, Ales $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Palecek, Tomas $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
- 773 0_
- $w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 11, č. 2 (2024), s. 859-870
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38204216 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155353 $b ABA008
- 999 __
- $a ok $b bmc $g 2080908 $s 1216356
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 11 $c 2 $d 859-870 $e 20240110 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251
- GRA __
- $p Charles University Research Program Cooperatio Cardiovascular Science
- LZP __
- $a Pubmed-20240412